Banner - Collaborative Care Symposium
News
All NewsContributorsMoney Matters
Media
All VideosExpert InterviewsMedical World NewsPodcastsCase Based Roundtable SeriesCase of the QuarterEyeViewGrand RoundsInsightsRapid ReadoutViewpointsWhat’s Your WhEYE?
Conferences
Conference CoverageConference Listing
Events
More
Publications
Digital EditionEurope Ophthalmology TimesModern RetinaSupplements and Featured Publications
CME
Partners
Resources
Job BoardSponsored

Subscribe

  • News
  • Media
  • Conferences
  • Events
  • Publications
  • CME
  • Partners
  • Subscribe
  • Resources
  • AMD
  • Biosimilars
  • COVID-19
  • Cataract
    • Cataract Surgery
  • Cataract Therapeutics
  • Clinical Diagnosis
    • The Residency Report
    • iOpeners
    • NeuroOp Guru
  • Cornea
  • DME
  • Dry Eye
    • Dry Eye Awareness
  • Gene Therapy
  • Geographic Atrophy
  • IOL
    • IOL Advances
  • Imaging
  • Interventional Glaucoma
    • Glaucoma Awareness
    • Glaucoma Insights
    • Therapeutic Glaucoma
  • OCT
  • Ocular Allergy
  • Ocular Surface Disease
  • Optic Relief
  • Optometry
  • Pediatrics
  • Pharmacy
  • Practice Management
    • Indispensable
  • Presbyopia
  • Ptosis
  • Refractive
    • Refractive Surgery
  • Retina
  • Surgery
  • Technology
  • Therapeutics
  • Understanding Antibiotic Resistance
  • Workplace
Spotlight -
Retina
Advertisement

Steven M. Archer, MD

Advertisement

Articles by Steven M. Archer, MD

Ophthalmoplegia surgical outcomes vary upon degree of eye paresis

BySteven M. Archer, MD,Fred Gebhart
June 14th 2018
Advertisement

Latest Updated Articles

  • Ophthalmoplegia surgical outcomes vary upon degree of eye paresis
    Ophthalmoplegia surgical outcomes vary upon degree of eye paresis

    Published: June 14th 2018 | Updated:



Advertisement
Advertisement

Trending on Ophthalmology Times - Clinical Insights for Eye Specialists

1

STAAR and Broadwood conflict over proposed Alcon merger continues

2

FDA clears IND for Complement Therapeutics’ CTx001 gene therapy in geographic atrophy

3

Increasing the knowledge base of GA is key to individualizing patient therapy

4

Ocular surface: Targeted therapies for a multifactorial problem

5

REGENXBIO completes enrollment in ATMOSPHERE and ASCENT trials of sura-vec in wet AMD

  • About
  • Advertise
  • Privacy
  • Editorial Info
  • Editorial Board
  • Terms and Conditions
  • Contact Us
  • Do Not Sell My Personal Information
  • Job Board
Contact Info

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

609-716-7777

  • Ophthalmology Times
  • Modern Retina
  • Optometry Times
  • Ophthalmology Times Europe
EyeCare Network
Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us